Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring

Peptides

Volumn 30, Issue 7, 2009, Pages 1276-1281

  Kheterpal, Indu ^a   Kastin, Abba J ^a   Mollah, Sahana ^b   Yu, Chuanhui ^a   Hsuchou, Hung ^a   Pan, Weihong ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b APPLIED BIOSYSTEMS   (United States)

Author keywords

Brain; Mass spectrometry; MIF 1; Multiple reaction monitoring (MRM); Peptidases; Peptide

Indexed keywords

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE; NEUROPEPTIDE; OXYTOCIN; PEPTIDASE; PROTEIN MIF 1; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HIPPOCAMPUS; HYPOTHALAMUS; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; THALAMUS; TISSUE HOMOGENATE;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HYPOTHALAMUS; MICE; MSH RELEASE-INHIBITING HORMONE; OXYTOCIN; TANDEM MASS SPECTROMETRY;

EID: 67349281746     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.04.004     Document Type: Article

References (54)

1. Banks W.A., and Kastin A.J. Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine. Peptides 15 (1994) 23-29
2. Barbeau A. Potentiation of levodopa effect by intravenous l-prolyl-l-leucyl-glycine amide in man. Lancet 2 (1975) 683-684
3. Bjorkman S., Castensson S., and Sievertsson H. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor. J Med Chem 22 (1979) 931-935
4. Burbach J.P., and Lebouille J.L. Proteolytic conversion of arginine-vasopressin and oxytocin by brain synaptic membranes. Characterization of formed peptides and mechanisms of proteolysis. J Biol Chem 258 (1983) 1487-1494
5. Burbach J.P., Schotman P., and de Kloet E.R. Oxytocin biotransformation in the rat limbic brain: chemical characterization of two oxytocin fragments and proposed pathway for oxytocin conversion. Biochem Biophys Res Commun 97 (1980) 1005-1013
6. Burbach J.P.H., Bohus B., Kovacs G., Van Nispen J., Greven H., and De Wied D. Oxytocin is a precursor of potent behaviourally active neuropeptides. Eur J Pharmacol 94 (1983) 125-131
7. Burbach J.P.H., De Kloet E., and De Wied D. Oxytocin biotransformation in the rat limbic brain: characterization of peptidase activities and significance in the formation of oxytocin fragments. Brain Res 202 (1980) 401-414
8. Castensson S., Sievertsson H., Lindeke B., and Sum C.Y. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides. FEBS Lett 44 (1974) 101-105
9. Celis M.E., and Taleisnik S. Formation of a melanocyte-stimulating hormone-release inhibiting factor by hypothalamic extracts from rats. Int J Neurosci 1 (1971) 223-230
10. Celis M., Taleisnik S., and Walter R. Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone. Proc Natl Acad Sci 68 (1971) 1428-1433
11. Chiu S., Wong Y.W., Ferris J.A., Johnson R.L., and Mishra R.K. Binding studies of l-prolyl-l-leucyl-glycinamide (PLG), a novel antiparkinsonian agent, in normal human brain. Pharmacol Res Commun 15 (1983) 41-51
12. Chiu S., Wong Y.W., Wan Y.P., Chiu P., and Mishra R.K. Are the pharmacological effects of l-prolyl-l-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry 7 (1983) 739-742
13. Dickinson S.L., and Slater P. A comparison of the effects of Pro-Leu-Gly NH2 and l-leucine on tremorine-induced tremor and rigidity in rats. J Pharm Pharmacol 34 (1982) 336-337
14. Durham D.A., Banks W.A., and Kastin A.J. Carrier-mediated transport of labeled oxytocin from brain to blood. Neuroendocrinology 53 (1991) 447-452
15. Ehrensing R.H., and Kastin A.J. Melanocyte-stimulating hormone-release inhibiting hormone as an anti-depressant: a pilot study. Arch Gen Psychiat 30 (1974) 63-65
16. Ehrensing R.H., and Kastin A.J. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression. Am J Psychiatry 135 (1978) 562-566
17. Ehrensing R.H., Kastin A.J., Wurzlow G.F., Michell G.F., and Mebane A.H. Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord 31 (1994) 227-233
18. Fischer P.A., Schneider E., Jacobi P., and Maxion H. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrome. Eur Neurol 12 (1974) 360-368
19. Gerstenbrand F., Poewe W., Aichner F., and Kozma C. In: Collu R. (Ed). Central nervous system effects of hypothalamic hormones and other peptides (1979), Raven Press, New York 415
20. Gerstenbrand F., Binder H., Kozma C., Pusch S.T., and Reisner T. Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl). Wien Klin Wochenschr 87 (1975) 822-823
21. Hatta K., Wolterink G., and Van Ree J. Prolyl-leucyl-glycinamide, thyrotropin-releasing hormone and beta-endorphin-(10-16), like antidepressants, antagonize melatonin-induced behavioural changes in rats. Eur J Pharmacol 284 (1995) 327-330
22. Huidobro-Toro J.P., De Carolis A.S., and Longo V.G. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of l-DOPA and 5-hydroxytryptophan in mice. Pharmacol Biochem Behav 2 (1974) 105-109
23. Huidobro-Toro J.P., Scotti dC, and Longo V.G. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II. Pharmacol Biochem Behav 3 (1975) 235-242
24. Kastin A.J., Abel D.A., Ehrensing R.H., Coy D.H., and Graf M.V. Tyr-MIF-1 and MIF-1 are active in the water wheel test for antidepressant drugs. Pharmacol Biochem Behav 21 (1984) 767-771
25. Kastin A.J., Hahn K., Zadina J.E., Banks W.A., and Hackler L. Melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1) can be formed from Tyr-MIF-1 in brain mitochondria but not in brain homogenate. J Neurochem 64 (1995) 1855-1859
26. Kastin A.J., Scollan E.L., Ehrensing R.H., Schally A.V., and Coy D.H. Enkephalin and other peptides reduce passiveness. Pharmacol Biochem Behav 9 (1978) 515-519
27. Kostowski W., Danysz W., Dyr W., Jankowska E., Krzascik P., Palejko W., et al. MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression. Peptides 12 (1991) 915-918
28. Larisch R., Klimke A., Vosberg H., Loffler S., Gaebel W., and Muller-Gartner H.W. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage 5 (1997) 251-260
29. Luciano M.G., Zadina J.E., Kastin A.J., and Coy D.H. Mu and delta opiate receptors in rat brain are affected by GTP but not by MIF-1. Brain Res Bull 7 (1981) 677-682
30. Marcotte E.R., Chugh A., Mishra R.K., and Johnson R.L. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1). Peptides 19 (1998) 403-406
31. Matsuo K., Rosenberg D.R., Easter P.C., MacMaster F.P., Chen H.H., Nicoletti M., et al. Striatal volume abnormalities in treatment-naive patients diagnosed with pediatric major depressive disorder. J Child Adolesc Psychopharmacol 18 (2008) 121-131
32. Nair R.M.G., Kastin A.J., and Schally A.V. Isolation and structure of hypothalamic MSH release-inhibiting hormone. Biochem Biophys Res Commun 43 (1971) 1376-1425
33. Niesink R.J., and van Ree J.M. Neuropeptides and social behavior of rats tested in dyadic encounters. Neuropeptides 4 (1984) 483-496
34. Pan W., and Kastin A.J. From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptides. Peptides 28 (2007) 2411-2434
35. Pelletier G., Labrie F., Kastin A.J., Coy D., and Schally A.V. Radioautographic localization of radioactivity in rat brain after intraventricular or intracarotid injection of 3H-l-prolyl-l-leucyl glycinamide. Pharmacol Biochem Behav 3 (1975) 675-679
36. Pignatiello M.F., Olson G.A., Kastin A.J., Ehrensing R.H., McLean J.H., and Olson R.D. MIF-1 is active in a chronic stress animal model of depression. Pharmacol Biochem Behav 32 (1989) 737-742
37. Plotnikoff N.P., and Kastin A.J. Oxotremorine antagonism by prolyl-leucyl-glycine amide administered by different routes and with several anticholinergics. Pharmacol Biochem Behav 2 (1974) 417-419
38. Plotnikoff N.P., Kastin A.J., Anderson M.S., and Schally A.V. DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci. 10 (1971) 1279-1283
39. Plotnikoff N.P., Kastin A.J., Anderson M.S., and Schally A.V. Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor, MIF. Proc Soc Exp Biol Med 140 (1972) 811-814
40. Plotnikoff N.P., Kastin A.J., Anderson M.S., and Schally A.V. Deserpidine antagonism by a tripeptide, l-prolyl-l-leucylglycinamide. Neuorendocrinology 11 (1973) 67-71
41. Plotnikoff N.P., Minard F.N., and Kastin A.J. DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide. Neuroendocrinology 14 (1974) 271-279
42. Pulvirenti L., and Kastin A.J. Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats. Eur J Pharmacol 151 (1988) 289-292
43. Rektorova I., Srovnalova H., Kubikova R., and Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. Mov Disord 23 (2008) 1580-1587
44. Schally A.V., and Kastin A.J. Purification of a bovine hypothalamic factor which elevates pituitary MSH levels in rats. Endocrinology 79 (1966) 768-772
45. Schneider E., Fischer P.A., Jacobi P., and Reh W. The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in Parkinsonian patients. Preliminary report (author's transl.). Arzneimittelforschung 28 (1978) 1296-1297
46. Shah P.J., Glabus M.F., Goodwin G.M., and Ebmeier K.P. Chronic, treatment-resistant depression and right fronto-striatal atrophy. Br J Psychiatry 180 (2002) 434-440
47. Sheng J.G., Xu D.L., Yu H.Z., Xu X.R., and Tang Q.M. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1). Life Sci 40 (1987) 2007-2010
48. Straub R.H., Wolff C., Fassold A., Hofbauer R., Chover-Gonzales A., Richards L.J., et al. Anti-inflammatory role of endomorphins in osteoarthritis, rheumatoid arthritis, and adjuvant arthritis. Rheumatology and Arthritis 58 (2008) 456-466
49. van der Velde C.D. Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness. Peptides 4 (1983) 297-300
50. Versteeg D. Neurohypophyseal hormones and brain neurochemistry. Pharmacol Ther 19 (1983) 297-325
51. Voith K., and Synthetic. MIF analogues. Part II. Dopa potentiation and fluphenazine antagonism. Arzneimittelforschung 27 (1977) 2290-2293
52. Walter R., Griffiths E., and Hooper K. Production of MSH-release-inhibiting hormone by a particulate preparation of hypothalami: mechanisms of oxytocin inactivation. Brain Res 60 (1973) 449-457
53. Zadina J.E., Hackler L., Ge L.-J., and Kastin A.J. A potent and selective endogenous agonist for the m-opiate receptor. Nature 386 (1997) 499-502
54. Zadina J.E., Martin-Schild S., Gerall A.A., Kastin A.J., Hackler L., Ge L.-J., et al. Endomorphins: a novel endogenous μ-opiate receptor agonist in regions of high μ-opiate receptor density. Ann NY Acad Sci 897 (1999) 136-144